Lactodel is a prescription medication utilized to assist in managing conditions related to elevated levels of the hormone prolactin, known as hyperprolactinemia. The medication is generally administered to help regulate symptoms and address the underlying hormonal imbalance in these specific conditions.

The medication's primary therapeutic focus is the treatment of hyperprolactinemic disorders, which may be idiopathic (of unknown cause) or due to prolactin-secreting pituitary adenomas (benign tumors). These disorders may contribute to symptoms like amenorrhea (absence of menstruation), galactorrhea (abnormal milk production), and issues with fertility.

The overall benefit to the patient is assistance with hormone normalization, which can stabilize associated symptoms and support improved function. The medication is indicated for use in these specific conditions.

Quick Fact: Relief for Hyperprolactinemia Symptoms

Eligibility Map: Who can and cannot use Lactodel — Official Regulatory Information

Populations for Whom Use is Prohibited (Contraindicated)

Lactodel is contraindicated and must not be used by patients with:

• Hypersensitivity (allergy) to bromocriptine, its excipients, or other ergot-related drugs.
• Uncontrolled hypertension or hypertensive disorders of pregnancy/postpartum (e.g., eclampsia, pre-eclampsia).
• A history of severe cardiovascular conditions, such as coronary artery disease, when the drug is used for non-life-threatening indications.
• A history of severe psychiatric disorders when the drug is used for non-life-threatening indications.
• Nursing women (due to the risk of serious maternal adverse effects and its effect on lactation).
• Cardiac valvulopathy (heart valve disease) when used for long-term treatment.

Restricted or Not Recommended Use

• Lactation Suppression: Routine use for preventing or stopping breast milk production is not recommended by regulatory bodies and should only be considered when medically indicated (e.g., intrapartum loss, neonatal death, or HIV infection). It is contraindicated in all women with underlying risk factors (hypertension, severe heart disease, or psychiatric history).
• Pediatric Population: Safety and efficacy have not been established for most uses in children. Use in children under 15 years of age is not recommended.
• Impairs Function: Use with caution in patients with hepatic impairment (liver disease) or renal impairment (kidney disease), as safety and efficacy have not been established. Patients with rare hereditary problems of galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption should not use this product.

Lactodel's interaction profile is documented by regulatory authorities, focusing on substances that alter its systemic exposure or primary pharmacological effect. The medication is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong CYP3A4 inhibitors (such as certain azole antifungals or HIV protease inhibitors) is advised to be avoided, as this significantly increases the plasma concentration and overall exposure of Lactodel due to reduced clearance. Conversely, CYP3A4 inducers are documented to decrease Lactodel's effectiveness by speeding up its clearance and reducing its circulating levels.

Combinations that oppose Lactodel's core action are designated as not recommended in prescribing information. This includes dopamine receptor antagonists and neuroleptics (e.g., metoclopramide), which can diminish the intended therapeutic effect through pharmacodynamic antagonism.

A specific interaction restriction applies to other ergot alkaloids; concurrent use is not recommended due to a heightened risk of additive vasoconstrictive effects. Official labeling may require a separation of administration by at least six hours between Lactodel and other ergot agents. Alcohol consumption is advised to be avoided during treatment due to the potential for increased central nervous system adverse effects. Additionally, caution is noted for patients with hepatic impairment, as slower metabolism may lead to higher and more prolonged plasma concentrations of Lactodel.

Lactodel functions by a specific series of intracellular biochemical interactions, primarily targeting key elements of the gastrointestinal regulatory system. Its biological target is the FPPS (farnesyl pyrophosphate synthase) enzyme, which is present on the surface of specific enteric cells.

The interaction type is a non-competitive, allosteric inhibition. Lactodel binds to a site on the FPPS enzyme distinct from the active substrate site, inducing a conformational change that lowers the enzyme's catalytic efficiency. This action prevents the FPPS-mediated production of farnesyl pyrophosphate.

This pathway modulation initiates a downstream mechanistic cascade. The lack of farnesyl pyrophosphate disrupts the prenylation and membrane localization of certain small GTPases, such as RhoA, which are critical regulators of cytoskeletal dynamics and cellular secretion. The subsequent alteration in GTPase activity modifies the signal transduction pathways responsible for fluid and electrolyte transport across the intestinal epithelium.

The final system-level physiological consequence is a localized change in the net transepithelial movement of water. By modulating this key intracellular cascade, Lactodel influences the balance of fluid in the intestinal lumen.

How to Use Lactodel

Lactodel, whose active ingredient is bromocriptine mesylate, is administered exclusively via the oral route. The medication is available in specific dosage forms, including 2.5 mg scored tablets and 5 mg capsules, with an additional 0.8 mg quick-release tablet used for a distinct indication.

Official Administration Guidelines

The fundamental principle of using Lactodel is gradual dose titration. Therapy typically begins with a low dose, such as 1.25 mg to 2.5 mg once daily. The dose is then slowly increased, usually in increments of 1.25 mg to 2.5 mg every 2 to 7 days, to reach the required maintenance level for the specific condition being managed.

Indication	Initial Dose Range	Maximum Daily Dose (Typical)
Hyperprolactinemia	1.25 mg to 2.5 mg daily	Up to 30 mg
Acromegaly / Parkinson's Disease	1.25 mg once or twice daily	Up to 100 mg

Administration Conditions

All standard formulations of Lactodel must be taken with food (meals or a snack) to improve tolerance. The initial daily dose for acromegaly is often specified to be taken at bedtime. Maintenance dosing is typically administered in divided doses throughout the day.

For older adults, caution is advised, often starting at the lower end of the dose range. Pediatric patients (ages 11–15) with hyperprolactinemia have specific initial and maintenance dose ranges, typically between 1.25 mg and 10 mg daily. The required duration of use is often long-term, and discontinuation should only be attempted following defined clinical criteria.

Research evidence / Overview of studies for Lactodel

This overview describes the types of clinical studies and research findings documented by regulatory and scientific bodies regarding the medicine Lactodel (bromocriptine mesylate). It focuses on what researchers have explored, the patterns observed so far, and where gaps or uncertainties remain in the evidence.

Evidence for Hyperprolactinemia and Prolactinomas

Research has primarily examined adult men and women with hyperprolactinemia, a condition characterized by high prolactin levels. Studies included short-term Randomized Controlled Trials (RCTs) and long-term observational follow-up studies. Researchers monitored physiological strain by measuring the normalization of serum prolactin levels and applied studies to examine outcomes related to systemic imbalance, such as the restoration of menstrual cycles (amenorrhea) and the suppression of galactorrhea (abnormal milk discharge).

Findings described how measured prolactin levels evolved in the observed populations. For prolactin-secreting tumors (prolactinomas), long-term monitoring included the measurement of changes in tumor volume. Research highlights patterns related to patient tolerability in certain subgroups, and data indicates that some patients demonstrate a limited or absent response, with patterns related to resistance observed more frequently in male patients with tumors.

Evidence for Use in Type 2 Diabetes Mellitus

The quick-release formulation of Lactodel was evaluated in large-scale Randomized, Placebo-Controlled Safety Trials that extended for 52 weeks. Research examined adult patients with Type 2 Diabetes Mellitus receiving diet, exercise, and/or other oral glucose-lowering agents. Studies monitored markers of glycemic control (e.g., A1C) and examined overall cardiovascular (CV) outcomes (macrovascular outcomes).

Clinical research notes limited available data regarding its use in combination with certain other anti-diabetic medications, such as thiazolidinediones, and comparative evidence is lacking for its use in combination with insulin. Follow-up durations were limited to 52 weeks for the primary safety and CV endpoint.

Evidence for Use in Other Endocrine and Neurological Conditions

For Acromegaly, evidence is derived from regulatory clinical summaries where research examined systemic imbalance by measuring circulating levels of serum Growth Hormone (GH). Studies reported variability in the degree of GH change recorded across patients. Research indicates that the effect on tumor size remains a controversial topic in the scientific literature.

For Parkinson's Disease, evidence is relevant in evidence describing how symptoms are measured for adults, typically those already receiving levodopa therapy. Studies explored short-term symptom changes by assessing motor signs and symptoms. The available evidence base is historical and largely precedes the introduction of many newer comparative agents; thus, comparative evidence is lacking for modern treatment scenarios.

Common questions about Lactodel (FAQ)

Q: Does Lactodel make you feel dizzy or sleepy?

Official product information, which includes data from clinical studies, lists dizziness and somnolence (sleepiness) as potential undesirable effects. The official product information typically advises caution regarding driving or operating heavy machinery until you know how the medication affects you. If you experience these effects, they are summarized in the regulatory documents.

Q: Is it safe to drink alcohol while taking Lactodel?

Regulatory documents indicate that the use of alcohol during treatment with Lactodel is generally not recommended or advised against. The regulatory documents indicate that combining this medication with alcohol may increase the risk of certain adverse effects.

Q: How should I store Lactodel?

Official storage instructions typically state that the product is to be stored at room temperature, away from moisture and light. Furthermore, these instructions specify that the medicine should be kept out of the sight and reach of children.

Q: Can children under 12 years old use Lactodel?

The official product information specifies the populations for whom this medicine is indicated. The drug is authorized and has specific dosing instructions for use in patients 12 years of age and older. No specific dosing is provided in the regulatory text for children under the age of 12.

Q: What happens if I miss a dose of Lactodel?

Regulatory instructions typically state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the regulatory text advises skipping the missed dose and continuing with the regular schedule. Official guidance also advises against taking a double dose to compensate for a missed one.

How to Store and Dispose of Lactodel (Bromocriptine Mesylate)

The medicine must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the product in its original container, which must be tightly closed and light-resistant, as the active ingredient is sensitive to light. Store Lactodel away from moisture and excess heat, and do not freeze it. For safety, the medication must be kept out of the sight and reach of children.

To dispose of expired or unused Lactodel, patients are required to ask a healthcare professional or pharmacist for proper guidance. Official guidelines caution against environmental release; therefore, the product should not be flushed down the toilet or disposed of in household trash due to its classification as extremely hazardous for water.